1 st: 29Mar2021/2nd:12May2021; This is a spontaneous report from a contactable other HCP (nurse). This other HCP (patient) reported in response to HCP letter  via follow-up letter which included that:  Memory problem, So I can remember all still having long covid symptoms of heart problems after injections.  Did the patient provide information to you regarding the reported adverse events(s) with the use of the product? Yes Iam the pt reporter these adverse events.  If yes above, do you consider the Pfizer product had a causal effect to the adverse event? Yes  Patient Age at Time of Vaccination:62 Years Pfizer/BioNTech COVID-19 vaccine details 1st dose: Date: 29Mar2021 Time(24hrs):08:30  Anatomical site of injection:Left arm Route of Administration:Intramuscular Batch/Lot number: Pfizer ER8730 2nd dose: Date: 12May2021 Time(24hrs):09:30  Anatomical site of injection:Left arm Route of Administration:Intramuscular Batch/Lot number: Pfizer EW0170  Concomitant drugs: Cardizem Dose:240 mg Reason for use: Tachycardia Route:PO Start date: April Ongoing: Yes  Patients medical history: Covid-19 Onset date:31Oct20 Ongoing: Yes  Tachycardia Onset date:28Nov20 Ongoing: Yes  Hypertension Onset date:years Ongoing: Yes  Asthma Onset date:years Ongoing: Yes  Family relevant medical history: Hypertension, Scoliosis.  Relevant tests: Covid-19 Date: 31Oct20 Result: POS  Covid adenots  Date: 07Nov20 Comments: Discharge 11Nov20  Tachycardia Date:27May20  Tachycardia Date:28Nov20  Chest pain Date:27May20  Chest pain Date:27Apr20  CT scans, EKG, Brain CT, Holter monitors, stress tests.  Adverse Events:  Onset date:27May2021 Time(24hrs):06:30 Serious Criteria: Hospitalization/prolongation of hosp, Important medical event Ae required to visit: Emergency room AE outcome: Recovered with sequelae Treatment: No Cardiazem continued  Onset date:04May2021 Serious Criteria: Persistent/significant/disability/incapacity ,  Important medical event AE outcome: Recovered with sequelae Treatment: No  Follow-Up (26Jul2021): Follow-up attempts are completed. No further information is expected. This is a spontaneous report from a contactable other hcp.   A 62-years-old patient of an unspecified gender received bnt162b2 (BNT162B2), dose 2 intramuscular, administered in Arm Left on 12May2021 (Batch/Lot Number: Pfizer EW0170) as DOSE 2, SINGLE for covid-19 immunisation  .  Medical history included , covid-19 from 31Oct2020 and ongoing Covid-19 , tachycardia from 28Nov2020 and ongoing  Tachycardia , ongoing hypertension  Hypertension , ongoing asthma Asthma , hypertension from an unknown date and unknown if ongoing Hypertension. Concomitant medication(s) included diltiazem (CARDIZEM [DILTIAZEM]) taken for tachycardia from an unspecified start date and ongoing.  The patient experienced 1 st: 29mar2021/2nd:12may2021 (inappropriate schedule of product administration) (non-serious) on an unspecified date with outcome of unknown.  The patient underwent lab tests and procedures which included cardiac stress test: unknown   on     , chest pain: unknown   on 27Apr2020   , chest pain: unknown   on 27May2020   , computerised tomogram: unknown   on     , computerised tomogram head: unknown   on     , electrocardiogram: unknown   on     , electrocardiogram ambulatory: unknown   on     , sars-cov-2 test: positive   on 31Oct2020   , tachycardia: unknown   on 27May2020   , tachycardia: unknown   on 28Nov2020  .  The action taken in response to the event(s) for bnt162b2 was not applicable.